Short-term Effects of 0.01% Atropine on Adult Myopes Pupil Size and Subjective Quality of Vision

Atropine2023-2

This aims to investigated the short-term (12, 16, and 20 h) effects of 0.01% atropine (0.1 mg/ml) on pupil size and subjective quality of vision in participants with myopia. Particpants will receive 0.01% atropine one drop to both eyes before bedtime. Baseline parameters were measured before atropine application. Changes in pupil sizes, under photopic and mesopic conditions, high-order aberration, and tear meniscus height were observed over the next day (12, 16, and 20 h).

2023-12-01

2023-12-15

2023-12-20

Not yet recruiting

40

Inclusion Criteria: * Diagnosed with myopia * Able to read and comprehend Chinese and willing to give informed consent as demonstrated by signing a record of informed consent. * Be between 18 and 60 years old, male or female. * Willing to apply eye drops once nightly at bedtime for one time and follow the clinical trial visit schedule as directed by the Investigator. * Willing to answer the questionnaire about subjective measurements. * Have ocular findings deemed to be myopic. * No history of wearing contact lens. * Vision correctable to at least 20/25 or better in each eye with spectacles. Exclusion Criteria: * Any pre-existing ocular irritation, injury or condition, including infection or disease. * Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. - - Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. * Use of or a need for concurrent ocular medication at enrolment and/or during the clinical trial. * Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. * History of eye surgery * History of use of any myopia control interventions such as Orthokeratology, Rigid Permeable Contact Lenses Eye surgery within 12 weeks immediately prior to enrolment for this trial. * Currently treated with other interventions for myopia control * Contraindications to atropine such as pulmonary disease, heart conditions and ADHD * Known allergy or intolerance to ingredients to atropine eye-drops and other derivatives of anti-muscarinic receptor agents. * Currently enrolled in another clinical trial. NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}

2023-10-30